Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Cibil Report
Get cibil report
My Account
Log In
Log into your account
Offers
Check out pre-approved offers now!
Languages
Chosen Language: English
Do Not Call
Do not call
En
Torrent Pharmaceuticals Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Low
₹4,532.00
High
₹4,672.00
Price Summary
| Previous Close | ₹4,613.40 |
|---|---|
| Day's Range | ₹4,532.00 - ₹4,672.00 |
| Open | ₹4,560.00 |
| 52 Week Range | ₹3,532.60 - ₹5,250.00 |
| Volume | 4,36,645 |
| Market Cap | ₹0.18 |
| Previous Close | ₹4,635.15 |
|---|---|
| Day's Range | ₹4,559.15 - ₹4,668.55 |
| Open | ₹4,559.15 |
| 52 Week Range | ₹3,532.85 - ₹5,249.95 |
| Volume | 62,448 |
| Market Cap | ₹0.18 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 20,181.51 |
|---|---|
| Market Cap (₹ in Mn) | 0.18 |
| Dividend Yield(%) | 0.82 |
| Price/Earning (TTM) | 83.01 |
| TTM EPS (₹) | 55.84 |
| P/E Ratio | 66.03 |
| Book Value(₹) | 9.60 |
| PAT Margin (%) | 10.86 |
| Face Value (₹) | 5.00 |
| ROCE(%) | 19.27 |
| Trade Value ( ₹ in Lacs) | 2,887.63 |
|---|---|
| Market Cap (₹ in Mn) | 0.18 |
| Dividend Yield(%) | 0.82 |
| Price/Earning (TTM) | 83.01 |
| TTM EPS (₹) | 55.84 |
| P/E Ratio | 66.03 |
| Book Value(₹) | 9.60 |
| PAT Margin (%) | 10.86 |
| Face Value (₹) | 5.00 |
| ROCE(%) | 19.27 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 33020.0 | 115160.0 |
| Expenses | N/A | N/A |
| PBT | 7910.0 | 26730.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 5910.0 | 19110.0 |
About Torrent Pharmaceuticals Ltd.
| Founded | 1972 |
|---|---|
| Managing Director | Aman Mehta |
| NSE Symbol | TORNTPHARM |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,26,661.74 | 1,778.25 | 1,583.70 - 1,583.70 |
| Divi's Laboratories Ltd. | 2,57,902.73 | 9,715.00 | 5,647.50 - 5,647.50 |
| Torrent Pharmaceuticals Ltd. | 1,76,306.21 | 4,635.15 | 3,532.60 - 3,532.60 |
| Laurus Labs Ltd. | 1,29,242.68 | 2,392.00 | 917.95 - 917.95 |
| Zydus Lifesciences Ltd. | 1,24,089.48 | 1,244.00 | 835.50 - 835.50 |
| Apollo Hospitals Enterprise Ltd. | 1,20,779.11 | 8,400.00 | 6,696.50 - 6,696.50 |
| Lenskart Solutions Ltd. | 1,17,959.74 | 678.20 | 0.00 - 0.00 |
| Dr. Reddy's Laboratories Ltd. | 1,12,698.53 | 1,350.20 | 1,101.00 - 1,101.00 |
| Cipla Ltd. | 1,11,488.55 | 1,380.00 | 1,165.70 - 1,165.70 |
| Mankind Pharma Ltd. | 1,02,796.60 | 2,488.75 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Oct
9
2026
Posted on Oct 9th 2026
Torrent Pharmaceuticals submits analyst meet intimation
Torrent Pharmaceuticals has informed that the Company has scheduled a teleconference with Investors/ Analysts on 23rd October, 2026 at 05:30 PM to discuss the financial performance of the Company for the quarter and half year ended 30th September, 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
Oct
31
2026
Posted on Oct 31st 2026
Narayana Hrudayalay. - Quaterly Results
The revenue zoomed 16.31% to Rs. 11853.77 millions for the quarter ended September 2026 as compared to Rs. 10191.69 millions during the corresponding quarter last year.Good Net Profit growth of 27.38% reported above the corresponding previous quarter figure of Rs. 1378.80 millions to Rs. 1756.26 millioins.Operating profit for the quarter ended September 2026 rose to 3045.61 millions as compared to 2461.39 millions of corresponding quarter ended September 2025.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 11853.77 | 10191.69 | 16.31 | 22824.79 | 19623.10 | 16.32 | 39751.41 | 35901.22 | 10.72 |
| Other Income | 433.50 | 170.88 | 153.69 | 737.63 | 335.24 | 120.03 | 1764.34 | 1421.63 | 24.11 |
| PBIDT | 3045.61 | 2461.39 | 23.74 | 5740.96 | 4415.93 | 30.01 | 10158.82 | 8137.02 | 24.85 |
| Interest | 352.30 | 285.78 | 23.28 | 688.96 | 592.01 | 16.38 | 1271.16 | 877.08 | 44.93 |
| PBDT | 2693.31 | 2175.61 | 23.80 | 5052.00 | 3823.92 | 32.12 | 8434.90 | 7259.94 | 16.18 |
| Depreciation | 501.09 | 462.66 | 8.31 | 982.57 | 938.24 | 4.72 | 1914.78 | 1692.63 | 13.12 |
| PBT | 2192.22 | 1712.95 | 27.98 | 4069.43 | 2885.68 | 41.02 | 6520.12 | 5567.31 | 17.11 |
| TAX | 435.96 | 334.15 | 30.47 | 934.62 | 633.17 | 47.61 | 1488.99 | 1255.89 | 18.56 |
| Deferred Tax | 17.03 | 18.36 | -7.24 | 34.58 | 30.77 | 12.38 | -75.93 | 187.21 | -140.56 |
| PAT | 1756.26 | 1378.80 | 27.38 | 3134.81 | 2252.51 | 39.17 | 5031.13 | 4311.42 | 16.69 |
| Equity | 2043.61 | 2043.61 | 0.00 | 2043.61 | 2043.61 | 0.00 | 2043.61 | 2043.61 | 0.00 |
| PBIDTM(%) | 25.69 | 24.15 | 6.39 | 25.15 | 22.50 | 11.77 | 25.56 | 22.67 | 12.75 |
Read More
Oct
31
2026
Posted on Oct 31st 2026
Anuh Pharma - Quaterly Results
A slight decline in the revenue of Rs. 1852.41 millions was seen for the September 2026 quarter as against Rs. 1858.83 millions during year-ago period.A good growth in profit of 47.33% reported to Rs. 112.13 millions over Rs. 76.11 millions of corresponding previous quarter.The company reported a good operating profit of 175.52 millions compared to 128.57 millions of corresponding previous quarter.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 1852.41 | 1858.83 | -0.35 | 3790.51 | 3723.62 | 1.80 | 7716.57 | 6615.15 | 16.65 |
| Other Income | 6.08 | 9.78 | -37.83 | 36.85 | 43.66 | -15.60 | 43.56 | 94.55 | -53.93 |
| PBIDT | 175.52 | 128.57 | 36.52 | 369.17 | 265.36 | 39.12 | 660.76 | 703.64 | -6.09 |
| Interest | 0.52 | 0.76 | -31.58 | 0.55 | 2.87 | -80.84 | 4.72 | 6.19 | -23.75 |
| PBDT | 175.00 | 127.81 | 36.92 | 368.62 | 262.49 | 40.43 | 656.04 | 697.45 | -5.94 |
| Depreciation | 24.52 | 28.62 | -14.33 | 48.85 | 53.77 | -9.15 | 113.82 | 87.39 | 30.24 |
| PBT | 150.48 | 99.19 | 51.71 | 319.77 | 208.72 | 53.21 | 542.22 | 610.06 | -11.12 |
| TAX | 38.35 | 23.08 | 66.16 | 93.38 | 49.60 | 88.27 | 131.75 | 136.53 | -3.50 |
| Deferred Tax | -0.99 | -4.92 | -79.88 | 12.72 | -3.30 | -485.45 | -18.44 | -16.52 | 11.62 |
| PAT | 112.13 | 76.11 | 47.33 | 226.39 | 159.12 | 42.28 | 410.47 | 473.53 | -13.32 |
| Equity | 501.12 | 501.12 | 0.00 | 501.12 | 501.12 | 0.00 | 501.12 | 250.56 | 100.00 |
| PBIDTM(%) | 9.48 | 6.92 | 36.99 | 9.74 | 7.13 | 36.67 | 8.56 | 10.64 | -19.50 |
Read More
Oct
31
2026
Posted on Oct 31st 2026
Sun Pharma. Inds. - Quaterly Results
The sales surged to Rs. 61419.20 millions, up 35.04% for the September 2026 quarter as against Rs. 45481.10 millions during the corresponding quarter previous year.Profit after tax for the quarter ended September 2026 reported a huge growth of 54.42% to Rs. 8712.90 millions from Rs. 5642.20 millions.Operating Profit saw a handsome growth to 17957.40 millions from 12563.80 millions in the quarter ended September 2026.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 61419.20 | 45481.10 | 35.04 | 118830.50 | 101429.90 | 17.16 | 207546.40 | 229774.00 | -9.67 |
| Other Income | 810.10 | 727.90 | 11.29 | 2211.80 | 1765.00 | 25.31 | 4193.30 | 3791.40 | 10.60 |
| PBIDT | 17957.40 | 12563.80 | 42.93 | 39001.20 | 32696.20 | 19.28 | 66000.20 | 72168.40 | -8.55 |
| Interest | 2769.60 | 2483.30 | 11.53 | 5554.40 | 4867.50 | 14.11 | 9478.40 | 9538.90 | -0.63 |
| PBDT | 15187.80 | 10080.50 | 50.67 | 33131.50 | 24952.30 | 32.78 | 51058.40 | 62629.50 | -18.48 |
| Depreciation | 3157.90 | 3363.00 | -6.10 | 6237.10 | 6472.20 | -3.63 | 13117.20 | 12867.40 | 1.94 |
| PBT | 12029.90 | 6717.50 | 79.08 | 26894.40 | 18480.10 | 45.53 | 37941.20 | 49762.10 | -23.75 |
| TAX | 3317.00 | 1075.30 | 208.47 | 7030.10 | 5387.30 | 30.49 | 11707.00 | 7481.30 | 56.48 |
| Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PAT | 8712.90 | 5642.20 | 54.42 | 19864.30 | 13092.80 | 51.72 | 26234.20 | 42280.80 | -37.95 |
| Equity | 2399.30 | 2399.30 | 0.00 | 2399.30 | 2399.30 | 0.00 | 2399.30 | 2399.30 | 0.00 |
| PBIDTM(%) | 29.24 | 27.62 | 5.84 | 32.82 | 32.24 | 1.82 | 31.80 | 31.41 | 1.25 |
Read More
Oct
31
2026
Posted on Oct 31st 2026
Ajanta Pharma - Quaterly Results
The sales moved up 41.37% to Rs. 17250.70 millions for the September 2026 quarter as compared to Rs. 12202.40 millions during the year-ago period.Profit after tax for the quarter ended September 2026 reported a huge growth of 52.24% to Rs. 3798.90 millions from Rs. 2495.30 millions.Operating Profit saw a handsome growth to 5697.10 millions from 3646.20 millions in the quarter ended September 2026.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 17250.70 | 12202.40 | 41.37 | 32137.40 | 24288.00 | 32.32 | 48459.20 | 43220.40 | 12.12 |
| Other Income | 526.20 | 750.30 | -29.87 | 1234.40 | 1156.60 | 6.73 | 2044.00 | 1198.70 | 70.52 |
| PBIDT | 5697.10 | 3646.20 | 56.25 | 10372.30 | 7346.50 | 41.19 | 14023.90 | 13245.90 | 5.87 |
| Interest | 7.90 | 7.30 | 8.22 | 15.50 | 14.60 | 6.16 | 25.90 | 46.00 | -43.70 |
| PBDT | 5689.20 | 3638.90 | 56.34 | 10356.80 | 7331.90 | 41.26 | 13998.00 | 13199.90 | 6.05 |
| Depreciation | 463.00 | 419.20 | 10.45 | 896.10 | 822.30 | 8.97 | 1687.70 | 1399.30 | 20.61 |
| PBT | 5226.20 | 3219.70 | 62.32 | 9460.70 | 6509.60 | 45.33 | 12310.30 | 11800.60 | 4.32 |
| TAX | 1427.30 | 724.40 | 97.03 | 2507.10 | 1464.60 | 71.18 | 2842.10 | 2631.70 | 7.99 |
| Deferred Tax | -158.10 | 64.70 | -344.36 | -94.60 | 97.60 | -196.93 | 76.00 | 51.40 | 47.86 |
| PAT | 3798.90 | 2495.30 | 52.24 | 6953.60 | 5045.00 | 37.83 | 9468.20 | 9168.90 | 3.26 |
| Equity | 250.70 | 250.70 | 0.00 | 250.70 | 250.70 | 0.00 | 250.70 | 250.70 | 0.00 |
| PBIDTM(%) | 33.03 | 29.88 | 10.52 | 32.27 | 30.25 | 6.70 | 28.94 | 30.65 | -5.57 |
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Torrent Pharmaceuticals Ltd. is ₹4,613.40 as of 2026-10-30.
The market capitalisation of Torrent Pharmaceuticals Ltd. is ₹176,306.21 as of 2026-10-30.
The 1-year return of Torrent Pharmaceuticals Ltd. is 1,011.00% as of 2026-10-30.
The P/E ratio of Torrent Pharmaceuticals Ltd. is 66.03 as of 2026-10-31.
The 52-week high and low of Torrent Pharmaceuticals Ltd. are ₹5,250.00 and ₹3,532.60, respectively, as of 2026-10-30.
View More
People Also Ask
Torrent Pharmaceuticals Ltd. manufactures a wide range of specialised branded generic medications. The company holds market presence in therapeutic segments such as cardiovascular, central nervous system, gastrointestinal, and women's healthcare products across India and global markets.
Torrent Pharmaceuticals Ltd. engages in partnerships by acquiring strategic domestic brands to expand its medical portfolio. The enterprise collaborates with healthcare professionals and hospitals to ensure its specialised chronic care medications are widely accessible to patients.
View More
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Loan Offers
My Accounts
Explore
